Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus.

Steven T. Wiersma, Brian McMahon, Jean Michel Pawlotsky, Chloe L Thio, Mark Thursz, Seng Gee Lim, Ponsiano Ocama, Gamal Esmat, Mendy Maimuna, David Bell, Marco Vitoria, Irina Eramova, Daniel Lavanchy, Geoff Dusheiko, Health Organization Department of Immunization, Vaccines World Health Organization Department of Immunization, Vaccines

Research output: Contribution to journalArticle

Abstract

Most of the estimated 350 million people with chronic hepatitis B virus (HBV) infection live in resource-constrained settings. Up to 25% of those persons will die prematurely of hepatocellular carcinoma (HCC) or cirrhosis. Universal hepatitis B immunization programmes that target infants will have an impact on HBV-related deaths several decades after their introduction. Antiviral agents active against HBV are available; treatment of HBV infection in those who need it has been shown to reduce the risk of HCC and death. It is estimated that 20-30% of persons with HBV infection could benefit from treatment. However, drugs active against HBV are not widely available or utilized in persons infected with HBV. Currently recommended antiviral agents used for treatment of human immunodeficiency virus (HIV) infection do not adequately suppress HBV, which is of great concern for the estimated 10% of the HIV-infected persons in Africa who are co-infected with HBV. Progressive liver disease has been shown to occur in co-infected persons whose HBV infection is not suppressed. In view of these concerns, an informal World Health Organization consultation of experts concluded that: chronic HBV is a major public health problem in emerging nations; all HIV-infected persons should be screened for HBV infection; HIV/HBV co-infected persons should be treated with therapies active against both viruses and that reduce the risk of resistance; standards for the management of chronic HBV infection should be adapted to resource-constrained settings. In addition, a research agendum was developed focusing on issues related to prevention and treatment of chronic HBV in resource-constrained settings.

Original languageEnglish (US)
Pages (from-to)755-761
Number of pages7
JournalLiver International
Volume31
Issue number6
StatePublished - Jul 2011
Externally publishedYes

Fingerprint

Chronic Hepatitis B
Virus Diseases
Hepatitis B virus
Therapeutics
HIV
Antiviral Agents
Hepatocellular Carcinoma
Immunization Programs
Hepatitis B
Liver Diseases

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Wiersma, S. T., McMahon, B., Pawlotsky, J. M., Thio, C. L., Thursz, M., Lim, S. G., ... World Health Organization Department of Immunization, Vaccines, H. O. D. O. I. V. (2011). Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus. Liver International, 31(6), 755-761.

Treatment of chronic hepatitis B virus infection in resource-constrained settings : expert panel consensus. / Wiersma, Steven T.; McMahon, Brian; Pawlotsky, Jean Michel; Thio, Chloe L; Thursz, Mark; Lim, Seng Gee; Ocama, Ponsiano; Esmat, Gamal; Maimuna, Mendy; Bell, David; Vitoria, Marco; Eramova, Irina; Lavanchy, Daniel; Dusheiko, Geoff; World Health Organization Department of Immunization, Vaccines, Health Organization Department of Immunization, Vaccines.

In: Liver International, Vol. 31, No. 6, 07.2011, p. 755-761.

Research output: Contribution to journalArticle

Wiersma, ST, McMahon, B, Pawlotsky, JM, Thio, CL, Thursz, M, Lim, SG, Ocama, P, Esmat, G, Maimuna, M, Bell, D, Vitoria, M, Eramova, I, Lavanchy, D, Dusheiko, G & World Health Organization Department of Immunization, Vaccines, HODOIV 2011, 'Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus.', Liver International, vol. 31, no. 6, pp. 755-761.
Wiersma, Steven T. ; McMahon, Brian ; Pawlotsky, Jean Michel ; Thio, Chloe L ; Thursz, Mark ; Lim, Seng Gee ; Ocama, Ponsiano ; Esmat, Gamal ; Maimuna, Mendy ; Bell, David ; Vitoria, Marco ; Eramova, Irina ; Lavanchy, Daniel ; Dusheiko, Geoff ; World Health Organization Department of Immunization, Vaccines, Health Organization Department of Immunization, Vaccines. / Treatment of chronic hepatitis B virus infection in resource-constrained settings : expert panel consensus. In: Liver International. 2011 ; Vol. 31, No. 6. pp. 755-761.
@article{6944465f26824c9f9b688945d1883154,
title = "Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus.",
abstract = "Most of the estimated 350 million people with chronic hepatitis B virus (HBV) infection live in resource-constrained settings. Up to 25{\%} of those persons will die prematurely of hepatocellular carcinoma (HCC) or cirrhosis. Universal hepatitis B immunization programmes that target infants will have an impact on HBV-related deaths several decades after their introduction. Antiviral agents active against HBV are available; treatment of HBV infection in those who need it has been shown to reduce the risk of HCC and death. It is estimated that 20-30{\%} of persons with HBV infection could benefit from treatment. However, drugs active against HBV are not widely available or utilized in persons infected with HBV. Currently recommended antiviral agents used for treatment of human immunodeficiency virus (HIV) infection do not adequately suppress HBV, which is of great concern for the estimated 10{\%} of the HIV-infected persons in Africa who are co-infected with HBV. Progressive liver disease has been shown to occur in co-infected persons whose HBV infection is not suppressed. In view of these concerns, an informal World Health Organization consultation of experts concluded that: chronic HBV is a major public health problem in emerging nations; all HIV-infected persons should be screened for HBV infection; HIV/HBV co-infected persons should be treated with therapies active against both viruses and that reduce the risk of resistance; standards for the management of chronic HBV infection should be adapted to resource-constrained settings. In addition, a research agendum was developed focusing on issues related to prevention and treatment of chronic HBV in resource-constrained settings.",
author = "Wiersma, {Steven T.} and Brian McMahon and Pawlotsky, {Jean Michel} and Thio, {Chloe L} and Mark Thursz and Lim, {Seng Gee} and Ponsiano Ocama and Gamal Esmat and Mendy Maimuna and David Bell and Marco Vitoria and Irina Eramova and Daniel Lavanchy and Geoff Dusheiko and {World Health Organization Department of Immunization, Vaccines}, {Health Organization Department of Immunization, Vaccines}",
year = "2011",
month = "7",
language = "English (US)",
volume = "31",
pages = "755--761",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Treatment of chronic hepatitis B virus infection in resource-constrained settings

T2 - expert panel consensus.

AU - Wiersma, Steven T.

AU - McMahon, Brian

AU - Pawlotsky, Jean Michel

AU - Thio, Chloe L

AU - Thursz, Mark

AU - Lim, Seng Gee

AU - Ocama, Ponsiano

AU - Esmat, Gamal

AU - Maimuna, Mendy

AU - Bell, David

AU - Vitoria, Marco

AU - Eramova, Irina

AU - Lavanchy, Daniel

AU - Dusheiko, Geoff

AU - World Health Organization Department of Immunization, Vaccines, Health Organization Department of Immunization, Vaccines

PY - 2011/7

Y1 - 2011/7

N2 - Most of the estimated 350 million people with chronic hepatitis B virus (HBV) infection live in resource-constrained settings. Up to 25% of those persons will die prematurely of hepatocellular carcinoma (HCC) or cirrhosis. Universal hepatitis B immunization programmes that target infants will have an impact on HBV-related deaths several decades after their introduction. Antiviral agents active against HBV are available; treatment of HBV infection in those who need it has been shown to reduce the risk of HCC and death. It is estimated that 20-30% of persons with HBV infection could benefit from treatment. However, drugs active against HBV are not widely available or utilized in persons infected with HBV. Currently recommended antiviral agents used for treatment of human immunodeficiency virus (HIV) infection do not adequately suppress HBV, which is of great concern for the estimated 10% of the HIV-infected persons in Africa who are co-infected with HBV. Progressive liver disease has been shown to occur in co-infected persons whose HBV infection is not suppressed. In view of these concerns, an informal World Health Organization consultation of experts concluded that: chronic HBV is a major public health problem in emerging nations; all HIV-infected persons should be screened for HBV infection; HIV/HBV co-infected persons should be treated with therapies active against both viruses and that reduce the risk of resistance; standards for the management of chronic HBV infection should be adapted to resource-constrained settings. In addition, a research agendum was developed focusing on issues related to prevention and treatment of chronic HBV in resource-constrained settings.

AB - Most of the estimated 350 million people with chronic hepatitis B virus (HBV) infection live in resource-constrained settings. Up to 25% of those persons will die prematurely of hepatocellular carcinoma (HCC) or cirrhosis. Universal hepatitis B immunization programmes that target infants will have an impact on HBV-related deaths several decades after their introduction. Antiviral agents active against HBV are available; treatment of HBV infection in those who need it has been shown to reduce the risk of HCC and death. It is estimated that 20-30% of persons with HBV infection could benefit from treatment. However, drugs active against HBV are not widely available or utilized in persons infected with HBV. Currently recommended antiviral agents used for treatment of human immunodeficiency virus (HIV) infection do not adequately suppress HBV, which is of great concern for the estimated 10% of the HIV-infected persons in Africa who are co-infected with HBV. Progressive liver disease has been shown to occur in co-infected persons whose HBV infection is not suppressed. In view of these concerns, an informal World Health Organization consultation of experts concluded that: chronic HBV is a major public health problem in emerging nations; all HIV-infected persons should be screened for HBV infection; HIV/HBV co-infected persons should be treated with therapies active against both viruses and that reduce the risk of resistance; standards for the management of chronic HBV infection should be adapted to resource-constrained settings. In addition, a research agendum was developed focusing on issues related to prevention and treatment of chronic HBV in resource-constrained settings.

UR - http://www.scopus.com/inward/record.url?scp=80053465684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053465684&partnerID=8YFLogxK

M3 - Article

C2 - 21645206

AN - SCOPUS:80053465684

VL - 31

SP - 755

EP - 761

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - 6

ER -